Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2019.6496Source: DataRank Database

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer is a research paper published in JAMA Oncology (2020). On theSindex it has a DataRank of 2.3. It has been cited 76 times, with 45 citing works in its 1-hop citation network.

N/A

2.3DataRank · unranked

Scored on demand from live citation data

Open Access76 citations · 45 citing works in its network

Download PDF

Cite:

Linked data & code

omim

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 5.41)OA: bronzeTopics (49)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 28%Citation Network 72%

Base Score Contribution

0.652

From this paper's citation signal

Citation Network Contribution

1.7

From 35 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 45 citers.

HSD3B1 genotype predicts castration resistance
Nature Reviews Urology20201 citations2 referencesContributes 0.347
Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
JAMA Network Open202239 citations19 referencesContributes 0.194
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Annals of Oncology202045 citations26 referencesContributes 0.147
Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
JAMA Network Open201962 citations38 referencesContributes 0.109
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib
Investigational New Drugs202120 citations33 referencesContributes 0.092

Authors (14)

Christopher J. Sweeney ORCID,Nima Almassi ORCID,Chad A. Reichard ORCID,C.A. Reddy ORCID,Hong Li ORCID

Live enrichment

PubMed:32053149 PMC:PMC7042830 OpenAlex:https://openalex.org/W3005901626

NCI NIH HHS

Grant: R01 CA190289

NCI NIH HHS

Grant: R01 CA236780

NCI NIH HHS

Grant: UG1 CA233277

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: U10 CA180794

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: UG1 CA233160

NCI NIH HHS

Grant: R01 CA172382

NCI NIH HHS

Grant: U10 CA180820

NCI NIH HHS

Grant: R01 CA168899

National Institutes of Health

Grant: 1R01CA172382-01

Elucidating a novel molecular biomarker for castration-resistant prostate cancer

National Institutes of Health

Grant: 3U10CA180820-02S3

ECOG-ACRIN Operations Center

National Institutes of Health

Grant: 5UG1CA233160-03

UM LAPs - UG1 Grant

National Institutes of Health

Grant: 5UG1CA233234-06

Case Comprehensive Cancer Center NCTN Lead Academic Participating Site

National Institutes of Health

Grant: 5UG1CA233270-02

Vanderbilt Network Lead Academic Participating Site for the NCTN

National Institutes of Health

Grant: 5UG1CA233196-03

Johns Hopkins University NCTN Lead Academic Site Program

National Institutes of Health

Grant: 4R01CA168899-04

Cooperative steroidogenic inhibition for treatment of advanced prostate cancer

National Institutes of Health

Grant: 5R01CA236780-06

Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer

National Institutes of Health

Grant: 5U10CA180794-04

ECOG-ACRIN Network Group Statistics and Data Management Center

FWCI

5.41

Citation Percentile

1.0%

Citation Trend

2019

2020

2021

2022

2023

2024

2025

2026

bronze

journalhttps://jamanetwork.com/journals/jamaoncology/articlepdf/2761192/jamaoncology_hearn_2020_oi_190110.pdf

publisherhttps://jamanetwork.com/journals/jamaoncology/articlepdf/2761192/jamaoncology_hearn_2020_oi_190110.pdf

journalhttps://doi.org/10.1001/jamaoncol.2019.6496

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32053149

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7042830

Fields of Study

Prostate Cancer Treatment and ResearchEstrogen and related hormone effectsSexual Differentiation and Disorders03 medical and health sciences0302 clinical medicine

MeSH Terms

DocetaxelAgedAllelesAndrogen AntagonistsGenotypeHumansMaleMiddle AgedMultienzyme ComplexesNeoplasm MetastasisProgesterone ReductaseRetrospective StudiesSteroid IsomerasesTreatment OutcomeDisease ProgressionDisease-Free SurvivalProstatic Neoplasms, Castration-Resistant

Keywords

MedicineProstate cancerOncologyGenotypeInternal medicineCastrationProstateCancerHormoneGeneGeneticsMaleProgesterone ReductaseAndrogen AntagonistsSteroid IsomerasesDocetaxelMiddle AgedDisease-Free SurvivalProstatic Neoplasms, Castration-ResistantTreatment OutcomeMultienzyme ComplexesDisease ProgressionHumansNeoplasm MetastasisAllelesAgedRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being